Posts by Harsh Singh, MD
-
An Expert’s Perspective on What Daraxonrasib Means for the Future of Pancreatic Cancer Care
Phase 3 RASolute 302 data showed daraxonrasib doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer. Mass General Brigham Cancer Institute is participating in the FDA-authorized expanded access program, with approximately 50 patients consented to date.
Biography
Harshabad (Harsh) Singh, MBBS, MD, is a medical oncologist and physician-scientist specializing in pancreatic and hepatobiliary cancers. He serves as Program Director for Hepatobiliary and Pancreas Oncology at the MGB Cancer Institute, where his work bridges clinical innovation and translational research. Dr. Singh's is a translational scientist who focuses on developing novel therapeutic strategies and biomarkers for pancreatic cancer to improve early detection and treatment response prediction. He is committed to building a collaborative, patient-centered program that advances discovery and care for individuals with HPB malignancies.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.